SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-033756
Filing Date
2022-06-21
Accepted
2022-06-21 08:21:26
Documents
14
Period of Report
2022-06-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea161829-8k_protara.htm   iXBRL 8-K 32592
2 SEPARATION AGREEMENT AND RELEASE, DATED AS OF JUNE 20, 2022, BY AND BETWEEN BLAI ea161829ex10-1_protara.htm EX-10.1 55691
3 PRESS RELEASE OF PROTARA THERAPEUTICS, INC. ISSUED JUNE 21, 2022 ea161829ex99-1_protara.htm EX-99.1 8392
  Complete submission text file 0001213900-22-033756.txt   292605

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tara-20220620.xsd EX-101.SCH 2962
5 XBRL LABEL FILE tara-20220620_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tara-20220620_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT ea161829-8k_protara_htm.xml XML 3613
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 221026135
SIC: 2836 Biological Products, (No Diagnostic Substances)